Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Date:3/17/2009

PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical and preclinical abstracts are expected to be the subject of poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2009 in Colorado:

  • "A Phase I, open-label, dose-escalation, multi-dose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin's lymphoma" (Abstract #1227), R. Thertulien - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Efficacy of MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model" (Abstract #838), B. Chen - Poster presentation from 8:00 to 12:00 p.m. local time on Sunday, April 19, 2009.

  • "The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates" (Abstract #1722), S. Gangwar - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Development of anti-Glypican 3 therapeutic antibodies" (Abstract #1233), L. Lu - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Efficacy and Toxicity of anti-mesothelin antibody drug conjugate" (Abstract #3235), C. Rao - Poster presentation from 8:00 to 12:00 p.m. local time on Tuesday, April 21, 2009.

Abstracts and information about the AACR and its Annual Meeting may be found at www.aacr.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada and Europe. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
2. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
3. Medarex to Present at the RBC Capital Markets Healthcare Conference
4. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
5. Medarex Announces 2008 Third Quarter Financial Results
6. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
7. Medarex to Present at the UBS Global Life Sciences Conference
8. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
9. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
10. Medarex Announces July 10 Live Webcast of R&D Day Event
11. Medarex to Present at the Jefferies Second Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently formed ... entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The ... gene editing across all applications. , Under the terms of the agreement, Pioneer ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
Breaking Biology Technology:
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use fingerprints instead ... National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in ... the boarding process to allow eligible Delta SkyMiles Members who are enrolled ...
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):